alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
exv10w14






Exhibit 10.14








	Infinite Fast Start Bonus
Personally Enrolled : 1-3rd 4th 5th
Also earn $50, and $35 bonuses infinitely deep on qualified Vantage Pack purchases in your
organization.
Purchase a Vantage Pack & qualify to earn an overide on all qualified Vantage Packs within your
organization




	Fast Start Bonus




	30% to Enroller w/PV between 100-199
40% to Enroller w/ Business Pack and 200 PV
minimum AutoShip*




	Receive 1 share for every 5 personal enrollments at 100 PV.
Royalty Commission / dynamically compressed




	Paid As Rank            Distributor            Pro 1 Pro 2 Pro 3 Pro 4 Pro 5 Pro 6 Pro 7 Pro 8 Pro 9 Pro 10




	Minimum Monthly PV** 100 100 100 100 200 200 200 200 200 200 200




	Minimum Monthly OV            N/A 1,000 2,500 5,000 10,000 20,000 50,000 100,000 200,000 500,000 1,000,000




	Minimum Leg Req. N/A 1 1 2 2 2 2 3 3 3 3




	Maximum % per Leg            N/A            N/A            N/A 80% 80% 70% 70% 60/30*** 60/30*** 60/30*** 40%




	1st 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2%




	2nd 5% 5% 5% 5% 5% 5% 5% 5% 5% 5% 5%




	Level 3rd 9% 9% 9% 9% 9% 9% 9% 9% 9% 9%




	4th 5% 5% 5% 5% 5% 5% 5% 5% 5%




	Placement




	5th 5% 5% 5% 5% 5% 5% 5% 5%




	6th 5% 5% 5% 5% 5% 5% 5%




	7th 5% 5% 5% 5% 5% 5%




	8th 5% 5% 5% 5% 5%




	9th 2% 2% 2% 2%




	Enroller            Gen
1 Gen 2 Gen 3 Gen 4 Gen 5




	30% Generational            youyou you            you            you




	Matching Bonus**** YOU




	earn 10%earn 5% earn 5% earn 5% earn 5%
Earn 10% match on the Unilevel Check of your personal enrollments. Earn additional 5% down 4




	enrollment generations of personal enrollments. You must enroll 1 person per month with 100 PV in
order to earn the Matching Bonus, through Pro 6.




	4% of total commissionable sales paid to




	4% Elite Pool            qualified Pro 7 through Pro 10 Distributors.




	*In order to qualify for the 40% Fast Start Bonus, you must purchase the Vantage Pack. This can be
done at the time of enrollment or via upgrade at a later date.




	**At least 30 PV must be Personal Volume. The remaining can come from your personally enrolled
Preferred Customer’s volume.




	***10% of the OV requirement must come from the equivalent of a third leg.




	****In order to earn a full generational match, you must maintain a minimum autoship of 200 PV. At
least 30 PV must be Personal Volume. The remaining can come from your personally enrolled Preferred
Customer’s volume. If your AutoShip is less than 200 PV, you will earn half of the Matching Bonus.




	The LifeVantage Compensation Plan is new and unique. Any charts, illustrations and stated examples




	of income under the plan are potential in nature and not based on the actual performance of any
individual.
Sarah Williams

Risk Oversight Officer November 4, 2022

Re: Weekly Notification of Rule Amendments 

– Updates to Risk Parameters Established by 

ICC Pursuant to Section 5c(c)(1) of the 

Commodity Exchange Act and Commission 

Regulation 40.6(d)

VIA ELECTRONIC PORTAL

Mr. Christopher Kirkpatrick

Secretary

Commodity Futures Trading Commission

Three Lafayette Centre

1155 21st Street, NW

Washington, D.C. 20581

Dear Mr. Kirkpatrick:

ICE Clear Credit (“ICC”) hereby submits, pursuant to Section 5c(c)(1) of the Commodity Exchange Act and 

Commodity Futures Trading Commission (“Commission”) Regulation 40.6(d), a notification of changes to 

risk parameters established by ICC in consultation with the ICC Risk Committee, Trading Advisory Group 

and/or Risk Working Group. ICC is registered with the Commission as a derivatives clearing organization.

The purpose of this notification is to report any changes to the risk parameters established by ICC. During 

the week ending November 4, 2022, changes were made to the following parameters: 

• recovery rates for a North American risk factor

ICC has posted a copy of this submission on its website concurrent with this filling. 

ICC would be pleased to respond to any questions the Commission or the staff may have regarding this 

submission. Please direct any questions or requests for information to the attention of the undersigned at 

sarah.williams@ice.com or (312) 836-6883.

Sincerely,

Sarah Williams

Risk Oversight Officer
Exhibit 32.2

CYCLE COUNTRY ACCESSORIES CORP.
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual report of Cycle Country Accessories
Corp. (the "Company") on Form
10-KSB for the twelve months ended September 30, 2008 (the
"Report"), I, Joan Brehmer, Acting Chief Financial Officer of the Company,
certify, pursuant to Section 18 U.S.C. 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations
of the Company.



/s/ Joan Brehmer
------------------------------------
Acting Chief Financial Officer
January 13, 2009






<PAGE>
**Exhibit 32.3**

 

CERTIFICATION PURSUANT TO SECTION 1350 OFCHAPTER 63 OF TITLE 18 OF THE UNITED STATES CODE

 

 

I,Gregg Buckbinder, the Chief Financial and Operating Officer and principalfinancial officer of Millburn Ridgefield Corporation, the Managing Owner ofGlobal Macro Trust (the “Trust”), certify that (i) the Annual Report ofthe Trust on Form 10-K for the period ending December 31, 2004fully complies with the requirements of Section 13(a) or 15(d) ofthe Securities Exchange Act of 1934 and (ii) the information contained insuch Annual Report fairly presents, in all material respects, the financialcondition and results of operations of the Trust.

 
| Date:  | March  30, 2005                        |   |   |
|--------|----------------------------------------|--------|--------|
|   | /s/ Gregg Buckbinder                   |   |
|   |  Gregg Buckbinder                 |
|   | Chief Financial  and Operating Officer |

 

----
Exhibit
32





CERTIFICATION
OF JAMES WATSON


PURSUANT
TO SECTION 906 OF THE SARBANES-OXLEY ACT





CERTIFICATION
PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002





In
connection with the Quarterly Report of Micro Mammoth Solutions, Inc. (the
“Company”) on Form 10-Q for the quarter ended December 31, 2009 as filed with
the Securities and Exchange Commission on or about the date hereof (“Report”),
the undersigned, in the capacities and on the date indicated below, hereby
certifies pursuant 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:





1.
            The
      Report fully complies with the requirements of Section 13(a) or 15(d) of
      the Securities Exchange Act of 1934;
and





2.
            The
      information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operations of the
      Company.





Date:    February
15, 2010





/s/ Christopher K.
    DaviesChristopher
      K. DaviesChief
      Executive Officer andPrincipal
      Accounting Officer
# C_2020399EN.01000701.xml

| 23.11.2020 | EN | Official Journal of the European Union | C 399/7 |
| --- | --- | --- | --- |

23.11.2020

EN

Official Journal of the European Union

C 399/7

---

Judgment of the Court (Second Chamber) of 24 September 2020 — Prysmian SpA, Prysmian Cavi e Sistemi Srl v European Commission, The Goldman Sachs Group Inc., Pirelli & C. SpA

(Case C-601/18 P) (1)

(Appeal - Competition - Cartels - European mark et for submarine and underground power cables - Market allocation in connection with projects - Single and continuous infringement - Succession of legal entities - Attributability of unlawful conduct - Principle of equal treatment - Distortion of evidence - Regulation (EC) No 1/2003 - Article 20 - European Commission’s powers of inspection in cartel proceedings - Power to copy data without a prior examination and to examine the data subsequently at the Commission’s premises - Fines)

(2020/C 399/09)

Language of the case: English

Parties

Appellants: Prysmian SpA, Prysmian Cavi e Sistemi Srl (represented initially by: C. Tesauro and L. Armati, avvocati, and subsequently by C. Firth and C. Griesenbach, Solicitors)

Other parties to the proceedings: European Commission (represented by: F. Castilla Contreras, C. Sjödin, T. Vecchi and P. Rossi, acting as Agents), The Goldman Sachs Group Inc. (represented by: J. Koponen, advokat, and A. Mangiaracina, avvocatessa), Pirelli & C. SpA (represented by: G. Rizza and M. Siragusa, avvocati)

Operative part of the judgment

The Court:

| 1. | Dismisses the appeal; |
| --- | --- |

1.

Dismisses the appeal;

| 2. | Declares that Prysmian SpA and Prysmian Cavi e Sistemi Srl shall bear their own costs and orders them to pay those incurred by the European Commission; |
| --- | --- |

2.

Declares that Prysmian SpA and Prysmian Cavi e Sistemi Srl shall bear their own costs and orders them to pay those incurred by the European Commission;

| 3. | Orders Pirelli & C. SpA to bear its own costs. |
| --- | --- |

3.

Orders Pirelli & C. SpA to bear its own costs.

---

(1)  OJ C 427, 26.11.2018.

---
Exhibit 32.1

CERTIFICATION PURSUANT TO

18 USC. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Golden
Pond Healthcare, Inc. (the Company) for the quarter ended September 30, 2008 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Stephen F. Wiggins, Chairman and
President of the Company, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:



| | (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



|                  |  |                                                        
|----------------- |  | -------------------------------------------------------
|November 14, 2008 |  | /s/ Stephen F. Wiggins                                 
|                  |  | Stephen F. Wiggins, Chairman of the Board and President
Exhibit
32.2




CERTIFICATION
PURSUANT TO


18 U.S.C.
SECTION 1350,


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002





In
connection with the Quarterly Report on Form 10-Q of SinoHub, Inc. (the
“Company”) for the quarter ending September 30, 2008 as filed with the
Securities and Exchange Commission on the date hereof (the “Report”), Tracy A.
Edwards, Chief Financial Officer of the Company, hereby certifies,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that to his knowledge:





(1)
            The
      report fully complies with the requirements of Section 13(a) or 15(d) of
      the Securities Exchange Act of 1934;
and





(2)
            The
      information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operations of the
      Company.






Dated:
       November 13, 2008
                By:
                /s/
      Tracy A. EdwardsTracy
      A. EdwardsChief
      Financial Officer
In the United States Court of Federal Claims 

OFFICE OF SPECIAL MASTERS

No. 15-901V

Filed: March 7, 2016

Unpublished

* * * * * * * * * * * * * * * * * * * * * * * * * * * *

JEANETTE STANCARONE, *

*

Petitioner, * Ruling on Entitlement; Concession;

* Influenza;

* Shoulder Injury (“SIRVA”);

SECRETARY OF HEALTH * Special Processing Unit (“SPU”)

AND HUMAN SERVICES, *

*

Respondent. *

*

* * * * * * * * * * * * * * * * * * * * * * * * * * * *

Robert Krakow, Law Office of Robert J. Krakow, PC, New York, NY, for petitioner.

Camille Michelle Collett, U.S. Department of Justice, Washington, DC, for respondent.

RULING ON ENTITLEMENT1

Dorsey, Chief Special Master:

On August 19, 2015, Petitioner filed a petition for compensation under the 

National Vaccine Injury Compensation Program, 42 U.S.C. §300aa-10, et seq.,

2 [the 

“Vaccine Act” or “Program”]. Petitioner alleges that she experienced a left shoulder 

injury following receipt of her October 6, 2014 influenza vaccination. Petition at 2-3. 

The case was assigned to the Special Processing Unit of the Office of Special Masters.

On March 4, 2016, respondent filed her Rule 4(c) report in which she concedes 

that petitioner is entitled to compensation in this case. Respondent’s Rule 4(c) Report

at 1. Specifically, respondent “believes that the alleged injury is consistent with a 

shoulder injury related to vaccine administration (“SIRVA”) and these conditions were 

caused in fact by the influenza vaccine she received on October 6, 2014.” Id. at 5. 

Respondent further agrees that no other cause of petitioner’s injury has been identified, 

 1 Because this unpublished ruling contains a reasoned explanation for the action in this case, the 

undersigned intends to post it on the United States Court of Federal Claims' website, in accordance with 

the E-Government Act of 2002. 44 U.S.C. § 3501 note (2012)(Federal Management and Promotion of 

Electronic Government Services). In accordance with Vaccine Rule 18(b), petitioner has 14 days to 

identify and move to redact medical or other information, the disclosure of which would constitute an 

unwarranted invasion of privacy. If, upon review, the undersigned agrees that the identified material fits 

within this definition, the undersigned will redact such material from public access.

2 National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755. Hereinafter, for 

ease of citation, all “§” references to the Vaccine Act will be to the pertinent subparagraph of 42 U.S.C. § 

300aa (2012).
that petitioner has suffered her condition for more than six months, and that petitioner 

has satisfied all legal prerequisites for compensation under the Vaccine Act. Id.

In view of respondent’s concession and the evidence before me, the 

undersigned finds that petitioner is entitled to compensation.

IT IS SO ORDERED.

s/Nora Beth Dorsey

Nora Beth Dorsey

Chief Special Master
```

[Federal Register Volume 66, Number 101 (Thursday, May 24, 2001)]
[Notices]
[Page 28757]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-13109]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director; Notice of Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of 
the Recombinant DNA Advisory Committee.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: June 14-15, 2001.
    Date: June 15-14, 2001.
    Time: 8:30 a.m. to 5 p.m.
    Agenda: The committee will review selected human gene transfer 
protocols; NIH policy on serious adverse event reporting; data 
management activities related to human gene transfer clinical 
trials; discussion on the risk group designation for E. coli strain 
B; and other matters to be considered by the Committee.
    Place: Natcher Building, Conference Room D, 45 Center Drive, 
Bethesda, MD 20892.
    Contact Person: Amy P. Patterson, MD, Acting Executive 
Secretary, Office of Biotechnology Activities, National Institutes 
of Health, 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892, 301-
496-9838.
    Information is also available on the Institute's/Center's home 
page: www4.od.nih.gov/oba/, where an agenda and any additional 
information for the meeting will be posted when available.

    Note: ``Mandatory Information Requirements for Federal 
Assistance Program Announcements'' (45 FR 39592, June 11, 1980) 
requires a statement concerning the official government programs 
contained in the Catalog of Federal Domestic Assistance. Normally 
NIH lists in its announcements the number and title of affected 
individual programs for the guidance of the public. Because the 
guidance in this notice covers virtually ever NIH and Federal 
research program in which DNA recombinant molecule techniques could 
be used, it has been determined not to be cost effective or in the 
public interest to attempt to list these programs. Such a list would 
likely require several additional pages. In addition, NIH could not 
be certain that every Federal program would be included as many 
Federal agencies, as well as private organizations, both national 
and international, have elected to follow the NIH Guidelines. In 
lieu of the individual program listing, NIH invites readers to 
direct questions to the information address above about whether 
individual programs listed in the Catalog of Federal Domestic 
Assistance are affected.

    Dated: May 17, 2001.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 01-13109 Filed 5-23-01; 8:45 am]
BILLING CODE 4140-01-M
```
EXHIBIT 31.2

                                  CERTIFICATION

I, Hugh Wain Swapp, certify that:

1. I have reviewed this Form 10-KSB/A of INTERNATIONAL CARD ESTABLISHMENT, INC.;

2. Based on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15-(e)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;

b) Evaluated the effectiveness of the registrant's disclosure controls and
procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and

c) Disclosed in this report any change in the registrant's internal control over
financial reporting that occurred during the registrant's most recent fiscal
quarter (the registrant's fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the
registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on
our most recent evaluation of internal control over financial reporting, to the
registrant's auditors and the audit committee of the registrant's board of
directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant's ability to record, process,
summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal control over
financial reporting.





DATE: NOVEMBER 22, 2005                 /S/ HUGH WAIN SWAPP
                                       ---------------------------
                                           HUGH WAIN SWAPP
                                           CHIEF FINANCIAL OFFICER
----

----

|   | 1. | the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2011, as filed with the Securities and Exchange Commission (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2. | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                                                                                                                                                                                                                 |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| /s/ BRIAN HALLADAY                                    |
| Brian Halladay                                                                                                                                                                                                                       |
| Chief Financial Officer                                                                                                                                                                                                              |
| (Principal Financial and Accounting Officer)                                                                                                                                                                     |

----